Search Clinical Trials in the European Union

Duration
Visits
Phase
Intake methods
Benefits
Drugs
Locations
Clinical Specialty
1641-1660 of 3,900 trials

Metastatic Non-Small Cell Lung Cancer: Zimberelimab and Domvanalimab Study

We are comparing a new treatment combination with chemotherapy to standard treatment for patients with untreated metastatic non-small cell lung cancer. This study aims to see which option may help improve survival and response rates.

Metastatic Non–Small Cell Lung CancerConfirmation phase (III)11-15 visitsNo PlaceboInvestigational MedicinesPartially RemoteOncology

Diabetic Macular Edema: Faricimab Treatment Study

We are exploring whether Faricimab can improve vision in patients with diabetic macular edema. The study also examines changes in eye health and treatment frequency over 12 months.

Diabetic Macular Edema>2 yearsMonitoring phase (IV)≤5 visitsNo PlaceboStandard MedicinesEndocrinologyOphthalmology

Everolimus for Bone and Muscle Health in the Elderly

We are studying whether everolimus can help prevent bone loss and improve muscle function in older adults. This research aims to address age-related health challenges.

Healthy Elderly Participants3-6 monthsStandard MedicinesInternal MedicineOrthopedics and Traumatology

Advanced Solid Tumors: BI-1206 with Pembrolizumab

We are studying a new treatment combining BI-1206 and pembrolizumab for patients with advanced solid tumors. This trial aims to find a safe dose and understand how well this combination works for those with specific types of cancer.

Malignant Solid Tumor>2 yearsSafety phase (I)Efficacy phase (II)>20 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementInternal MedicineOncology

Advanced Cancers: BI-1808 Monoclonal Antibody

We are studying a new treatment called BI-1808 for people with advanced cancers, both alone and with pembrolizumab. The goal is to assess its safety and how well it is tolerated by patients.

Malignant Solid Tumor>2 yearsSafety phase (I)Efficacy phase (II)11-15 visitsNo PlaceboInvestigational MedicinesOncology

Colon Cancer: Personalized Treatment Strategy

We are exploring whether a blood-based genomic approach can improve outcomes for patients with operable Stage III and high-risk Stage II colon cancer compared to standard chemotherapy. This study also looks at side effects and quality of life.

Colorectal Cancer>2 yearsConfirmation phase (III)No PlaceboStandard MedicinesInternal MedicineOncology

Acetyl-L-Carnitine for ALS Treatment

We are studying whether acetyl-L-carnitine can help slow down the progression of ALS and improve quality of life. Participants will receive different doses to see which is most effective and safe.

Amyotrophic Lateral Sclerosis6-12 monthsEfficacy phase (II)Confirmation phase (III)6-10 visitsInvestigational MedicinesNeurology

Multiple Myeloma: Mezigdomide vs. Pomalidomide

We are studying whether a new drug, mezigdomide, combined with bortezomib and dexamethasone, is more effective than pomalidomide with the same drugs for patients with relapsed or refractory multiple myeloma.

Relapsed or Refractory Multiple Myeloma≤3 monthsConfirmation phase (III)>20 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementHematologyOncology

Diffuse Large B-cell Lymphoma: Loncastuximab and Epcoritamab Study

We are studying a combination of two medications for patients with relapsed or refractory diffuse large B-cell lymphoma. The goal is to see how well this treatment works and its safety compared to existing options.

Diffuse Large B-Cell Lymphoma (DLBCL)Follicular Lymphoma (FL) Grade 3BHigh-Grade B-Cell Lymphoma (HGBL)>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesHematologyOncology

Liver Cirrhosis: Stopping Proton-Pump Inhibitors

We are studying whether stopping proton-pump inhibitors helps or harms patients with liver cirrhosis compared to those who continue the medication. This trial looks at hospitalizations, infections, and overall health outcomes.

Liver Cirrhosis1-2 yearsConfirmation phase (III)Monitoring phase (IV)6-10 visitsStandard MedicinesGastroenterologyInternal Medicine

Antiplatelet Therapy Reduction in High Bleeding Risk Patients

We are studying whether lowering the dose of antiplatelet medication helps patients with acute coronary syndrome who have had stents placed, while reducing the risk of bleeding. The trial compares different medication regimens to find the best balance between safety and effectiveness.

Acute Coronary Syndrome>2 yearsConfirmation phase (III)No PlaceboInvestigational MedicinesCardiologyInternal Medicine

DOK7 Congenital Myasthenic Syndrome: ARGX-119 Study

We are investigating the safety and tolerability of a new treatment, ARGX-119, for adults with DOK7 Congenital Myasthenic Syndrome. This study aims to understand how well the treatment is tolerated in this specific group.

Congenital Myasthenic Syndrome1-2 yearsSafety phase (I)Efficacy phase (II)Internal MedicineNeurology

Severe von Willebrand Disease: Vonicog Alfa Prophylaxis

We are studying whether vonicog alfa can help prevent bleeding episodes in children with severe von Willebrand disease. The trial will also look at the safety of this treatment over time.

Von Willebrand Disease1-2 yearsConfirmation phase (III)6-10 visitsNo PlaceboStandard MedicinesCost ReimbursementPartially RemoteHematology

Non-Small Cell Lung Cancer: Osimertinib with Datopotamab Deruxtecan

We are studying the safety and effectiveness of combining osimertinib with datopotamab deruxtecan in patients with advanced non-small cell lung cancer that has an EGFR mutation. This trial aims to see if the combination works better than osimertinib alone.

Non-Squamous Non-Small Cell Lung Cancer>2 yearsConfirmation phase (III)Post-Trial Drug AccessNo PlaceboStandard MedicinesPartially RemoteOncology

Refractory Generalized Myasthenia Gravis: KYV-101 Therapy

We are studying a new CAR T-cell therapy for individuals with refractory generalized myasthenia gravis. The goal is to evaluate its safety and effectiveness in improving muscle strength.

Myasthenia GravisRefractory Generalized Myasthenia Gravis>2 yearsEfficacy phase (II)No PlaceboInvestigational MedicinesInfectious DiseasesNeurology

Alzheimer’s Disease: Trontinemab Study

We are assessing how a new monoclonal antibody, Trontinemab, behaves in the brains of healthy individuals and those with Alzheimer’s disease. This study aims to understand its distribution and retention in the brain.

Alzheimer's Disease3-6 monthsSafety phase (I)Neurology

Lower Limb Trauma: Rivaroxaban vs. Heparin

We are studying whether Rivaroxaban is as effective as low-molecular weight heparin in preventing blood clots in patients with lower limb injuries. This trial is for those at high risk of complications while in a cast or brace.

Lower Limb Trauma Requiring Immobilization≤3 monthsConfirmation phase (III)No PlaceboInvestigational MedicinesCardiologyOrthopedics and Traumatology

Stroke Treatment: Thrombolysis for Patients on Factor Xa Inhibitors

We are studying whether intravenous thrombolysis can improve recovery in stroke patients who have recently taken Factor Xa inhibitors. This trial compares the effects of this treatment to standard care options.

Acute Ischemic Stroke>2 yearsConfirmation phase (III)No PlaceboStandard MedicinesCost ReimbursementPartially RemoteInternal MedicineNeurology

Mantle Cell Lymphoma: Zanubrutinib with Rituximab

We are comparing a new treatment combining Zanubrutinib and Rituximab to standard therapy for patients with untreated mantle cell lymphoma who cannot have a stem cell transplant. The goal is to see which treatment works better and is safer.

Mantle Cell Lymphoma>2 yearsEfficacy phase (II)Confirmation phase (III)>20 visitsNo PlaceboStandard MedicinesCost ReimbursementHematologyOncology

Difelikefalin for Itching in Adolescents on Hemodialysis

We are studying whether difelikefalin is safe for adolescents aged 12 to 17 who have moderate-to-severe itching related to long-term kidney disease. This trial aims to help improve care for young patients undergoing hemodialysis.

Generalized ItchingChronic Kidney Diseases3-6 monthsEfficacy phase (II)>20 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesPartially RemoteDermatologyNephrologyPediatrics